Skip to main content

Aura Biosciences Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

AURA$7.66+16.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

June 30, 2024December 31, 2023
Assets
Current assets:
Cash and cash equivalents$30,075$41,063
Marketable securities157,341185,087
Restricted cash and deposits—19
Prepaid expenses and other current assets8,1805,625
Total current assets195,596231,794
Restricted cash and deposits, net of current portion768768
Right of use assets - operating lease18,14118,854
Other long-term assets443509
Property and equipment, net3,3343,150
Total Assets$218,282$255,075
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable1,4591,787
Short-term operating lease liability2,7542,687
Accrued expenses and other current liabilities6,3357,883
Total current liabilities10,54812,357
Long-term operating lease liability16,28016,870
Total Liabilities26,82829,227
Commitments and Contingencies (Note 12)
Stockholders’ Equity:
Common stock, $0.00001 par value, 150,000,000 authorized at June 30, 2024 and December 31, 2023, and 49,583,358 and 49,350,788 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively——
Additional paid-in capital518,988512,617
Accumulated deficit(327,351)(287,308)
Accumulated other comprehensive loss(183)539
Total Stockholders’ Equity191,454225,848
Total Liabilities and Stockholders’ Equity$218,282$255,075
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.